Drug Trial Radar · NCT01538966
Acromegaly Combination Treatment Study
Last checked: Nov 20, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
76
Actual
Start
Mar 29, 2012
Primary completion
May 20, 2022
Study completion May 20, 2022
Sponsor
- Lead sponsor
- Cedars-Sinai Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 27, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study the investigators will evaluate whether combination low dose somatostatin receptor ligand (SRL) and weekly or daily pegvisomant will attain equivalent control of serum insulin-like growth factor (IGF)-1 levels at a lower cost, compared to combination high dose SRL and weekly pegvisomant. Lower doses of therapy will greatly reduce cost of acromegaly therapy.
Conditions
- Acromegaly
Interventions
PegvisomantDrug
Octreotide LARDrug
LanreotideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cost EffectivenessTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.